Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

DDII Digital Forum: Resilience, smarter labs, therapeutics, and capital flows

Published

on

The Drug Discovery Innovators & Investors (DDII) Digital Forum, taking place on 30 September 2026, will bring together experts from across the drug discovery ecosystem to examine the scientific, operational and commercial developments shaping the future of early-stage drug discovery.

Following the announcement of the preliminary speaker lineup, we are now revealing further details of three of the four sessions featured in the programme.

Beyond Borders: Building a Collaborative and Resilient Drug Discovery Ecosystem, moderated by Reece Armstrong, Editor at Drug Discovery World (DDW), will examine how companies are navigating scale-up challenges, regulatory and geographical barriers, and resource management across clinical development. Kirsten Detrick (Basel Area Business & Innovation), Shrijay Vijayan (Polaryx Therapeutics), Peter Milner (Renexxion), and Grant Carr (Curia), will share real-world perspectives on building resilience and collaboration in a turbulent market.

Working Smarter: Strategies for Improving Lab Effectiveness, moderated by Diana Turner, Deputy Editor at DDW, will explore how early-stage drug discovery professionals can improve processes, optimise workflows and become more efficient. Christine Allen (Intrepid Labs), Elodie Siney (Oxford North), and Tom Valentin (CSEM) will discuss the role of new technology in expediting drug discovery processes, and the importance of applying lean methodologies to reduce costs and get products to market sooner.

Therapies and Modalities Changing Global Drug Discovery, moderated by Megan Thomas, Content Team at DDW, will examine the rapidly evolving therapeutic landscape, including cell therapies, gene editing and RNA. Melinda Duer (University of Cambridge), Steve Wedge (Cancer Research Horizons), Louise Modis (Amphista Therapeutics), and Caroline Barelle (Elasmogen) will explore the modalities having the biggest impact, how research and commercial planning are managed in these areas, and how advanced scientific approaches are creating new opportunities and addressing hard-to-treat diseases.

Where Next? Emerging Markets, Capital Flow and the New Frontiers of Drug Discovery, moderated by Patrik Frei, Founder and CEO of Venture Valuation Inc and Biotechgate, will explore the emerging therapeutic areas and technologies shaping the future of drug discovery, and examine where capital is flowing across Europe, the US and China. Julia Moore (Breakout Ventures), Johnny Habchi (Medicines Discovery Catapult), and Reuben Dawkins (Link Biologics) will share insights into the current financing landscape, evolving preferences across funding stages, and practical advice for biotech companies seeking investment.

These three sessions form part of the four-session programme. Further details on the final panel will be announced shortly.

The Forum is available to delegates across two regional time blocks – one timed for Europe and one for the Americas. Registration is open for both the Europe and Americas sessions, allowing attendees to join the programme at a time that suits their region.

Register here for Europe Forum: https://event.gotowebinar.com/event/bab960cb-c367-42c1-b4f5-9b8c0c9e6acd

Register here for Americas Forum: https://event.gotowebinar.com/event/36348c15-804c-4f9a-8b43-e67bd9c449b6

The Digital Forum is supported by Lead Sponsor Curia.

The post DDII Digital Forum: Resilience, smarter labs, therapeutics, and capital flows appeared first on Drug Discovery World (DDW).

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New webinar: Tackling drug discovery challenges in cancer research

Published

on

Cancer cells

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.

You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.

Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.

Q&A with the speakers follows the presentations.

Register for free now.

The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).

Continue Reading

Uncategorized

Psilocybin proves promising in neuropathic pain mouse study

Published

on

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.

Continue Reading

Uncategorized

New Spectrometry Technique Could Aid Formulation Development

New Spectrometry Technique Could Aid Formulation Development

Published

on

A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.

According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.

“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”

Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.

The challenge is understanding the link between these things within a heterogeneous sample, he says.

To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.

He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.

Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.

Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read